Changes of intracardiac hemodynamics in patients with decreased myocardial contractility at transplantation of cord blood stem cells

Abstract

Until now, ischemic heart disease and chronic heart failure (HF) remain the biggest problem of health care in the world [1]. Due to diseases of cardiovascular system and reduction of heart pumping function millions of people live with HF [2]. There were developed many methods of HF treatment, but in some cases they do not solve the problem. One of the newest and prospective approaches is stem cells (SCs) transplantation. In most researches SCs transplantation led to significant improvement of contractile ability of the left ventricle (LV) myocardium in both animals [3] and people [4,5] at ischemia lesion. It was proved that stem cells improve patients' survival and quality of life [6]. However, several other studies have shown a chance of complications and adverse side effects at SCs transplantation [7][8][9]. These differences are explained by the use of SCs from various sources and, consequently, with different properties.Experiments on animals have shown an effectiveness of cord blood SCs in restoration of myocardial contractility [10][11][12][13] MATERIALS AND METHODS. According to the data echocardiography we analyzed the changes of intracardiac hemodynamics in patients with decreased myocardial contractility, who underwent intravenous transplantation of cord blood stem cells in case of ineffective traditional conservative therapy schemes of heart failure (HF). RESULTS. Left ventricular ejection fraction before cord blood stem cells transplantation was 22.0 ± 5.0%, 1 month after

Stem cell therapy for cardiac regeneration: key points

“…In the short term (1-3 months) after the transplantation of cord blood mononuclear cells, there was a demonstrated partial recovery of left ventricular systolic function by echocardiography and a significant improvement in impaired heart mechanics. No negative effects, complications, or side effects have been detected in the short periods of observation after cord blood-derived cell transplantation [50].…”

The long-term outcomes of cell c ardiomyoplast y in patients with refractory angina

“…Однак дотепер існує потреба в розробці оп тимальної комбінації лікування хворих на ІХС, ускладнену ішемічною дисфункцією міокар да, котрі не мають можливості для первинної або повторної прямої реваскуляризації, яка дасть змогу збільшити віддалену виживаність, поліпшити якість життя та збільшити його три валість. Залишається також предметом дис кусії найбільш ефективний спосіб доставки клітин у міокард [8][9][10][11][12]. Досліджень на дану тему у доступній літературі недостатньо, а існуючі дослідження безсистемні.…”